SM
PDSB icon

Sabby Management’s PDS Biotechnology PDSB Stock Holding History

Sabby Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-376
Closed -$305K – 182
2021
Q4 		$305K Buy
376
+92
+32% +$990 0.04% 127
2021
Q3 		$423K Buy
+284
New +$3.54K 0.06% 122

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sabby Management's PDSB Position: Q4 2020 in Review

Sabby Management sold out of PDS Biotechnology (PDSB) in Q4 2020, closing a stake of 419,836 shares — an estimated $978K sold.

Sabby Management first reported a position in PDSB in Q3 2020 and held it in 1 quarter. The position peaked at $978K in Q3 2020. 30 funds tracked by Wall St. Rank hold PDSB as of Q4 2020.

  • Sabby Management reported no remaining PDS Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Sabby Management sold 419,836 PDS Biotechnology shares in Q4 2020, an estimated $978K.
  • Sabby Management first reported a position in PDS Biotechnology in Q3 2020 and held it in 1 quarter.
  • Sabby Management's PDS Biotechnology position peaked at $978K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.